SoftBank, Cormorant lead hefty $210M injection for Umoja's three-in-one cancer immunotherapy play
Umoja Biopharma has scored some bold backers for its grand vision to reshape cancer immunotherapies.
The Seattle-based biotech is tying the bow around a $210 million Series B that features prominent crossover players: SoftBank Vision Fund 2, Cormorant Asset Management, RTW Investments, Temasek, Presight Capital, Caas Capital, and an investment fund associated with SVB Leerink. Execs declined an interview, a move that fits into an increasingly common playbook pointing to an IPO next.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.